The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.
Ruth E Langley
Consultant or Advisory Role - Bayer
Honoraria - Aspirin Foundation
Richard H. Wilson
Consultant or Advisory Role - Hospira; Merck Serono; Roche; Sanofi
Alistair E. Ring
No relevant relationships to disclose
Howard Gordon Kynaston
No relevant relationships to disclose
David A. Cameron
No relevant relationships to disclose
Christopher Coyle
No relevant relationships to disclose
Duncan Charles Gilbert
No relevant relationships to disclose
Carlo Patrono
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Sam Rowley
No relevant relationships to disclose
Claire Murphy
No relevant relationships to disclose
David Adlam
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Richard Hubner
No relevant relationships to disclose
Tim Iveson
No relevant relationships to disclose
Robert J Steele
No relevant relationships to disclose
Anne L. Thomas
No relevant relationships to disclose
Timothy J Underwood
No relevant relationships to disclose
Janusz Jankowski
Research Funding - AstraZeneca
Expert Testimony - CRUK
Sudeep Gupta
No relevant relationships to disclose
Conjeevaram S Pramesh
No relevant relationships to disclose
Mahesh Parmar
No relevant relationships to disclose